REGENXBIO Announces Positive Interim Data and Update for Phase I/II Trial of RGX-121 for the Treatment of MPS II

– Consistent reductions in CSF levels of heparan sulfate up to 2 years after administration, as well as continued developmental skill acquisition – Initial data from Cohort 2 indicates evidence of systemic enzyme expression and biomarker activity – Additional data from Cohorts 1 and 2 to be

No Comments

Comments are closed.